Calyxt, a developer of gene-edited crop traits spun out of Cellectis, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The New Brighton, MN-based company was founded in 2010. It has not disclosed a proposed ticker or exchange. Calyxt filed confidentially on May 15, 2017. Citi, Credit Suisse and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
